Takeda expands Japan trial of elritercept for lower-risk MDS anemia
The Phase 2 study raised its enrollment target 56% to 42 patients as it started dosing, positioning Takeda's activin-A trap alongside its three other elritercept trials testing the same biology in transfusion-dependent MDS.
Executive Summary
- Takeda increased the target enrollment for a Phase 2 trial of its activin-A ligand trap in Japanese patients with lower-risk myelodysplastic syndromes as the study opened recruiting, a scale-up rather than a data readout.
- The trial tests whether the drug can restore transfusion independence and raise hemoglobin in a Japanese population, one of four elritercept studies Takeda is running in the same disease area, so its design choices carry forward to how the broader program reads.
- Elritercept sits in a field with an active direct comparator on the same activin-A pathway already in late-stage testing, and Takeda's own larger Phase 3 trials in the same indication carry more weight toward any approval decision.
- The trial's primary completion is not expected until mid-2028, well ahead of Takeda's larger elritercept Phase 3 programs already recruiting toward earlier completion windows.
The change
Takeda's registry filing shows the Japan-only Phase 2 trial (NCT07319845) moved from Not yet recruiting to Recruiting on July 16, 2026, with its anticipated enrollment target raised 56%, from 27 to 42 participants. The trial dosed its first patients starting April 22, 2026, and is running across 20 sites. Its anticipated primary completion date held steady at June 26, 2028. NCT07319845+1A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesNCT07319845Takeda Enrollment Increased in Phase 2 TAK-226 Trial for Anemia in Myelodysplastic SyndromesJul 16, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The study enrolls two cohorts: transfusion-dependent patients, whose primary endpoint is the percentage achieving transfusion independence for at least 8 weeks through week 24, and non-transfusion-dependent patients, whose primary endpoint is a hemoglobin increase of at least 1.5 g/dL sustained over the same window without a red-cell transfusion. Elritercept is delivered subcutaneously every four weeks as a ligand trap targeting activin A, activin B, GDF8 and GDF11, a mechanism intended to correct the ineffective erythropoiesis that drives anemia in lower-risk MDS. NCT07319845A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesNCT07319845
Where it sits in Takeda's program
This is one of four active elritercept trials Takeda is running, including two Phase 3 studies in the same indication: a 300-patient trial comparing the drug against epoetin alfa (NCT07422480, projected completion April 2029) and a 225-patient placebo-controlled trial (NCT06499285, projected completion May 2028). Both larger trials test transfusion-independence endpoints similar to this one, so the Japan-only cohort functions as a supporting readout within a program whose registrational weight rests with the Phase 3 studies. NCT07319845A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesNCT07319845
Competitive field
Bristol-Myers Squibb's luspatercept, which shares the activin-A target and ligand-trap mechanism, is already active in a Phase 4 trial in myelodysplastic syndromes, making it the closest direct comparator to elritercept in this indication. GlaxoSmithKline's momelotinib, tested in combination with luspatercept for transfusion-dependent myelofibrosis, and Takeda's own elritercept program in myelofibrosis round out the direct-comparator tier, while activin-A programs from Merck, Regeneron and Biohaven target unrelated indications such as pulmonary arterial hypertension and obesity. Against a comparator already in Phase 4, the informative bar for elritercept's own MDS program is less about proving the mechanism works and more about whether its transfusion-independence rates and hemoglobin responses hold up against luspatercept's established profile in the same setting.
Trial health
The registry recorded no primary-completion-date slippage and no endpoint amendments alongside the enrollment change, and the amendment record shows one prior update since the study's first submission in January 2026. Takeda's broader Myeloid Neoplasms trial portfolio has completed all five prior studies tracked in that area. NCT07319845A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic SyndromesNCT07319845
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.